NCT06290050View on ClinicalTrials.gov

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

May 3, 2024

Study Completion Date

May 16, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

Midazolam

Midazolam syrup.

DRUG

Repaglinide

Repaglinide tablets.

DRUG

TAK-279

TAK-279 capsules.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY